Block listing Interim Return REPLACEMENT | 26-Apr-2024 | 09:51 | RNS |
Block Listing Six Monthly Return | 26-Apr-2024 | 07:00 | RNS |
Block Listing Application to AIM | 23-Apr-2024 | 09:43 | RNS |
Notice of Results | 23-Apr-2024 | 07:00 | RNS |
Issue of Equity and Total Voting Rights | 22-Apr-2024 | 12:14 | RNS |
Avacta Reports Data at the AACR Annual Meeting | 09-Apr-2024 | 17:00 | RNS |
AVA6000 Abstract Release by AACR | 08-Apr-2024 | 07:00 | RNS |
Update on AVA6000 Phase 1a Clinical Trial Progress | 21-Mar-2024 | 07:00 | RNS |
Result of General Meeting | 18-Mar-2024 | 13:26 | RNS |
Avacta Announces AVA6000 Poster at AACR | 06-Mar-2024 | 07:00 | RNS |
Result of REX Retail Offer | 05-Mar-2024 | 07:00 | RNS |
Result of Placing | 29-Feb-2024 | 07:00 | RNS |
Proposed REX Retail Offer | 28-Feb-2024 | 16:42 | RNS |
Proposed Fundraise to progress Therapeutics | 28-Feb-2024 | 16:41 | RNS |
Share Incentive Plan/Issue of Equity | 16-Feb-2024 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 48.30p |
Change Today | -0.50p |
% Change | -1.02 % |
52 Week High | 159.60 |
52 Week Low | 44.50 |
Volume | 3,024,260 |
Shares Issued | 359.04m |
Market Cap | £173.42m |
RiskGrade | 461 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 2 |
Neutral | 0 |
Sell | 1 |
Strong Sell | 0 |
Total | 3 |
No dividends found |
Time | Volume / Share Price |
17:08 | 9,500 @ 48.30p |
16:41 | 184,531 @ 49.41p |
16:35 | 39,618 @ 48.30p |
16:35 | 18,987 @ 48.30p |
16:35 | 17,879 @ 48.30p |
CEO | Alastair Smith |
CFO | Tony Peter Gardiner |
You are here: research